WWP1 E3 ubiquitin ligase has previously been shown to be frequently amplified and overexpressed in prostate and breast cancers. However, the mechanism of WWP1 action is still largely unknown. p63, a member of the p53 family of transcription factors, has an important function in tumor development by regulating apoptosis. Using alternative promoters, p63 can be expressed as DNp63 and TAp63. Increasing evidence suggests that TAp63 sensitizes cells to apoptosis but DNp63 has an opposite function. In this study, we show that WWP1 binds, ubiquitinates, and destructs both DNp63a and TAp63a. The proteinprotein interaction occurs between the PY motif of p63 and the WW domains of WWP1. The knockdown of WWP1 by siRNA increases the endogenous DNp63a level in the MCF10A and 184B5 immortalized breast epithelial cell lines and confers resistance to doxorubicin-induced apoptosis. On the other hand, the knockdown of WWP1 increases the endogenous level of TAp63a, induces apoptosis, and increases sensitivity to doxorubicin and cisplatin in the HCT116 colon cancer cell line in a p53-independent manner. Finally, we found that DNA damage chemotherapeutic drugs induce WWP1 mRNA and protein expression in a p53-dependent manner. These data suggest that WWP1 may have a context-dependent role in regulating cell survival through targeting different p63 proteins for degradation.
The WW domain containing E3 ubiquitin protein ligase 1 (WWP1) belongs to the C2-WW-HECT type E3 family, which comprises eight other members including NEDD4, AIP4/Itch, SMURF1, and SMURF2. 1 All family members share a distinctive domain structure: a C2 domain at the N terminus for calcium-dependent phospholipid binding, 2-4 WW domains in the middle for protein-protein interaction with PY motifs, and a HECT domain at the C terminus for the ubiquitin transfer. Four family members including WWP1, 2,3 NEDD4, 4 SMURF1, 5 and SMURF2, 6 have been shown to be overexpressed in different tumor types.
WWP1 is a potential oncogene that undergoes genomic amplification and overexpression in a subset of prostate and breast cancers. 2, 3 The WWP1 gene is located at 8q21, a chromosomal region frequently amplified in human prostate and breast cancers. About 31-51% of cancer samples show gene copy number gains for WWP1. Furthermore, WWP1 is overexpressed in 58-60% of prostate and breast cancer samples. Functionally, WWP1 knockdown significantly suppresses cell proliferation and/or induces apoptosis in several prostate and breast cancer cell lines, 2, 3 suggesting that WWP1 could be a promising molecular target for cancer therapy.
WWP1 is an intrinsic E3 ubiquitin ligase for multiple important proteins involved in tumorigenesis. The transforming growth factor-b signaling pathway is well known to suppress epithelial proliferation and induce apoptosis but promote tumor development at later stage. Several studies suggest that WWP1 negatively regulates the TGF-b signaling by targeting its molecular components, including TGF-b receptor 1 (TbR1), 7 Smad2, 8 and Smad4 9 for ubiquitinmediated degradation. In addition, WWP1 has been reported to target several oncogenic factors such as Notch, 10 Runx2 11 and KLF5 12 for ubiquitin-mediated proteolysis. Recently, WWP1 has been demonstrated to inhibit p53 activity through exporting p53 from the nucleus by ubiquitination. 13 However, the role of WWP1 in tumorigenesis remains to be elucidated.
The p63 transcription factor, a member of the p53 family, shares DNA binding, oligomerization and possible transactivation (TA) domains with p53 and p73. 14 Using alternative promoters, p63 can be expressed as DNp63 and TAp63 that have opposite functions in transcription control. 15 There are three isoforms (a, b, g) for both TAp63 and DNp63 because of the RNA splicing. 16 All TAp63 isoforms contain an N-terminal p53-like transactivation domain which can transactivate traditional p53 target genes. Like p53, TAp63 promotes apoptosis through the death receptor and mitochondrial pathways. In contrast to TAp63, increasing evidence suggests that DNp63 isoforms could be oncoproteins with an antiapoptotic activity. All DNp63 isoforms lack the TA domain but still contain the DNA-binding domain and oligomerization domain, suggesting that DNp63 may function as dominantnegative forms of TAp63. Indeed, the DNp63 isoforms have been shown to act as transcriptional repressors both in vitro and in vivo and strongly oppose the function of TAp63, TAp73 and p53. 16 Numerous studies have shown that DNp63a is the predominate isoform expressed in epithelial tissues including epidermis, prostate and breast. 16 p63 knockout mice fail to develop skin, prostate and mammary glands among other defects because of depletion of stem cells. 17, 18 Similarly, inhibition of the endogenous DNp63a expression by RNAi induces epithelial apoptosis. 19, 20 In addition, the ectopic expression of DNp63 in fibroblast cells induces anchorageindependent growth and tumor growth in nude mice. 21 All p53 family members are degraded through the ubiquitinproteasome pathway. 22 Multiple E3 ligases including Mdm2, ARF-BP, Cop1 and Pirh2 have been demonstrated to target p53 for ubiquitin-mediated degradation. 22 The receptor of activated protein C kinase-Elongin-C/B ubiquitin ligase complex has been proposed to be an E3 ligase for DNp63a. 23 Recently, two WWP1 family members, Itch and Nedd4 have been shown to promote ubiquitination and degradation of the p63 proteins. 24, 25 In addition, the inhibition of Itch potentiates the killing effect of doxorubicin in HeLa cells. 26 Given the frequent expression alteration of WWP1 in human cancers, it is important to know whether WWP1 regulates apoptosis through promoting p63 degradation. Here, we show that WWP1 targets both DNp63a and TAp63a for ubiquitin-mediated proteasomal degradation. Importantly, we demonstrate that WWP1 regulates apoptosis and drug sensitivity in a p63-dependent manner. Lastly, we found WWP1 is induced by DNA damage therapeutic drugs in a p53-dependent manner. These findings help us understand the mechanism of WWP1 action in human cancer and may provide better designs for future cancer treatment.
Results
WWP1 interacts with p63a through the WW/PY motifs. The p63a protein has been shown to interact with Itch and Nedd4 through the PY/WW motif interaction. 24, 25 To test whether WWP1 interacts with p63a, we first tested if p63a can be co-immunoprecipitated with WWP1. A plasmid expressing Myc-WWP1C886S (a catalytic inactive mouse WWP1 mutant) and plasmids expressing either FLAGDNp63a or FLAG-TAp63a were transfected into LinX cells. Myc-WWP1C886S was efficiently immunoprecipitated by the anti-Myc antibody ( Figure 1a ). We found that both FLAGDNp63a and FLAG-TAp63a are co-immunoprecipitated with Myc-WWP1C886S. The anti-Myc antibody itself cannot immunoprecipitate the p63a proteins without the expression of Myc-WWP1C886S, suggesting that the interactions are specific.
Then we tested whether the protein-protein interaction between WWP1 and p63a is through the WW/PY motifs. We Figure 1 The WWP1 protein interacts with p63a proteins through the WW/PY motifs in mammalian cells. (a) Both FLAG-DNp63a and FLAG-TAp63a are co-precipitated with Myc-WWP1C886S. LinX cells were co-transfected with different combinations of expression plasmids for Myc-WWP1C886S, FLAG-DNp63a and FLAG-TAp63a. IP was performed using anti-Myc Ab. Myc-WWP1C886S was probed by anti-WWP1 Ab. The catalytic inactive WWP1 mutant was used to avoid p63 degradation by WT WWP1. b-actin serves as a loading control for the input. (b) Both FLAG-DNp63a and FLAG-TAp63a interact with WWP1 through the PY motif. FLAG-DNp63aY449F and FLAG-TAp63aY543F are two p63a mutants in which the PY motifs are disrupted by substituting the Tyr (Y) residue with the Phe (F) residue. The Myc-WWP1C886S-transfected LinX (without FLAG-p63a) was used as a negative control. (c) WWP1 binds to FLAG-DNp63a but not FLAG-DNp63aY449F through WW domains, as determined by GST pull-down assays. Four WW domains of WWP1 were individually or collectively expressed as GST fusion proteins in LinX cells. (d) The endogenous WWP1 protein forms a complex with the endogenous DNp63a protein in MCF10A. The WWP1 protein was probed with the rabbit anti-WWP1 antibody. The same amount of mouse IgG nonspecifically immunoprecipitated few DNp63a after extensive washing. However, anti-WWP1 Ab immunoprecipitated much more DNp63a than the IgG control under the same conditions. (e) The endogenous WWP1 protein forms a complex with the endogenous TAp63a protein in HCT116 mutated the PY motifs in p63a (Y449F for DNp63a and Y543F for TAp63a) and performed immunoprecipitation (IP) with these mutants. We found that both PY motif-mutated p63a proteins cannot efficiently interact with Myc-WWP1C886S (Figure 1b) , suggesting that the PY motifs in DNp63a and TAp63a are required to interact with WWP1. Following that, we asked which WW domain of WWP1 participates in the protein interaction with p63a. We fused each of the four WW domains of WWP1 to the C terminus of GST and performed GST pull-down assays with FLAG-DNp63a in LinX cells. As shown in Figure 1c , GST itself does not pull down any FLAGDNp63a, but all four GST-WW proteins pull down different amounts of FLAG-DNp63a. The GST-WW1 protein pulls down much more FLAG-DNp63a than the rest of GST-WW proteins, although the expression levels of GST-WW and FLAG-DNp63a are similar in the different groups. Consistently, GST-WW (1-2) pulls down more FLAG-DNp63a than GST-WW (3-4). These findings suggest that the first WW domain may have a major function for p63a binding. Consistent with the results in Figure 1b , both GST-WW1 and GST-WW (1-2) pull down WT but not the PY motifmutated DNp63a (Figure 1c , right panel). Taken together, the protein interaction between WWP1 and p63a is through the WW/PY motifs.
Finally, we immunoprecipitated the endogenous WWP1 proteins from MCF10A by using anti-WWP1 Ab and found that the endogenous DNp63a protein is in the same complex (Figure 1d ). Similarly, we detected protein interaction between endogenous WWP1 and endogenous TAp63a in HCT116 (Figure 1e ). These results suggest that the protein interaction between WWP1 and p63a could occur at the physiological level.
WWP1 ubiquitinates p63a in cultured mammalian cells. As the WWP1 E3 ligase interacts with both DNp63a and TAp63a, we next determined whether WWP1 ubiquitinates the p63a proteins in mammalian cells. To this end, we transfected the expression constructs for WT hWWP1 or the catalytic inactive mutant hWWP1C890A, FLAG-DNp63a or FLAG-TAp63a, and Myc-Ub into LinX cells. We performed IP with the anti-FLAG antibody conjugated M2 beads under a denaturing condition to eliminate any p63a-associated proteins through non-covalent bonds. The ubiquitin-conjugated p63a proteins were detected by western blot with anti-Myc Ab. As shown in Figure 2a , WT WWP1 significantly increases the ubiquitination of both TAp63a and DNp63a compared with the vector control, whereas the catalytic inactive WWP1C890A does not. We noticed that WWP1 shows a higher ubiquitination activity towards the DNp63 isoform compared with the TAp63 isoform. The format of p63 ubiquitination by WWP1 is most likely polyubiquitination because a smear of band above the unmodified p63a was detected for both TAp63a and DNp63a. These results indicate that WWP1 polyubiquitinates both DNp63a and TAp63a through its E3 ligase activity.
In addition, we examined the ubiquitination of the PY motifmutated DNp63aY449F and TAp63aY543F by WWP1. As shown in Figure 2b , WWP1 only ubiquitinates WT p63a but not PY motif-mutated p63a under the same conditions. We conclude that the protein interaction is essential for WWP1 to ubiquitinate p63a.
To investigate whether endogenous WWP1 contributes to the endogenous DNp63a ubiquitination, we knocked down WWP1 in MCF10A by a WWP1 siRNA and examined the ubiquitination of DNp63a. Compared with the Luc siRNA, the WWP1 siRNA efficiently silenced the WWP1 protein expression, elevated the DNp63a protein level and decreased the ubiquitinated DNp63a.
WWP1 promotes p63a proteasomal degradation. To test whether WWP1 targets p63a for degradation, we first Figure 2 WWP1 ubiquitinates p63a proteins in mammalian cells. (a) WWP1 ubiquitinates both TAp63a and DNp63a using its E3 ligase activity. LinX cells were co-transfected with expressing plasmids for Myc-Ub, WWP1, WWP1C890A, FLAG-DNp63a and FLAG-TAp63a, as indicated. The cells were treated with 20 mM proteasome inhibitor MG132 overnight to accumulate the ubiquitinated p63a before harvest. The IP was performed with the anti-FLAG M2 beads under denaturing conditions. Immunoblotting was performed with the indicated Abs. The ubiquitin modified p63a proteins were detected by anti-Myc Ab. As majority of FLAG-DNp63a is polyubiquitinated by WWP1, much less unmodified FLAG-DNp63a was detected when WWP1 is co-transfected. (b) WWP1 specifically ubiquitinates WT but not PY motif-mutated p63a. (c) Endogenous WWP1 ubiquitinates endogenous DNp63a in MCF10A. WWP1 was knocked down by siRNA#1. Luc siRNA was used as a control. MG132 was not added. IP was performed under a denaturing condition using anti-p63 Ab and protein A beads WWP1 targets p63 for degradation Y Li et al measured the steady-state levels of both TAp63a and DNp63a in the presence and absence of WWP1. As shown in Figure 3a , the steady-state levels of both TAp63a and DNp63a are decreased in WT WWP1, but not in WWP1C890A, overexpressing LinX cells. To further determine whether the protein interaction between p63a and WWP1 is required for degradation of p63a, we measured the steady-state protein level of DNp63aY449F in the presence of WWP1 or WWP1C890A. As expected, WT WWP1 fails to decrease the steady-state level of DNp63aY449F (Figure 3a) .
To further investigate whether the decrease of p63a by WWP1 is because of the increase of protein degradation, we measured the half-lives of DNp63a and TAp63a in the presence and absence of WWP1 by cycloheximide (CHX) chase assays. As shown in Figure 3b , both the DNp63a and TAp63a proteins have a long half-life (410 h) in LinX cells. When WT WWP1 is overexpressed, the half-lives are dramatically decreased to about 3.2 h for DNp63a ( Figure 3c ) and about 7.5 h for TAp63a ( Figure 3d ). The catalytic inactive WWP1C890A only slightly decreases the half-life of DNp63a and TAp63a when compared with the empty vector (Figure 3c and d). As the PY motif mutant p63a cannot interact with WWP1, we wondered whether WWP1 cannot decrease the half-lives of these mutant p63a. Indeed, we found that both DNp63aY449F and TAp63aY543F are resistant to WWP1-mediated degradation (Figure 3b-d) .
The degradation of p63a by WWP1 is most likely through the proteasome as p63a is polyubiquitinated by WWP1. To test if the proteasome is involved in p63a degradation by WWP1, we performed CHX chase assays in the presence of the proteasome inhibitor MG132 (10 mM). As shown in Figure  3 (b-d), WWP1-induced p63a degradation is blocked by MG132, suggesting that the degradation of p63a by WWP1 is through the 26S proteasome.
We also confirmed that endogenous WWP1 decreases protein half-life of endogenous DNp63a. The WWP1 protein was knocked down by siRNA in MCF10A, the DNp63a protein half-lives were measured by pulse chase assays. As shown in Supplementary Figure S1 , WWP1 knockdown dramatically extended the half-life of the endogenous DNp63a protein.
WWP1 targets the endogenous DNp63a protein for degradation and sensitizes immortalized breast epithelial cells to chemotherapeutic drug doxorubicininduced apoptosis. To determine whether WWP1 targets p63a under physiological conditions, we knocked down endogenous WWP1 in two immortalized breast epithelial cell lines MCF10A and 184B5 by two different anti-WWP1 siRNAs. We found that the protein levels of endogenous DNp63a, the major p63 isoform in MCF10A and 184B5, are remarkably elevated in both cell lines when WWP1 is knocked down by both siRNAs (Figure 4a ). These results It has been reported that DNp63a is essential for MCF10A to survive. 19 Therefore, elevation of DNp63a may confer resistance to apoptosis. To test this, we treated siRNA-transfected MCF10A cells with different dosages of doxorubicin for 2 days and measured the cells viability by SRB assays. The high concentration of doxorubicin (X1 mM) kills all MCF10A cells at the same efficiency (Figure 4b) . However, the WWP1 knockdown MCF10A cells are significantly more resistant to low concentrations (0.25-0.5 mM) of doxorubicin than the Ctrl-si-transfected cells. Two different anti-WWP1 siRNAs show similar results although Wsi#2 is slightly more effective than Wsi#1 possibly because of inducing more DNp63a (Figure 4a ). We further measured apoptosis by the Annexin V staining. As shown in Figure 4c , Wsi#1 significantly (Po0.01) reduced doxorubicin (0.5 mM) induced Annexin V positive cells. We also confirmed apoptosis by the measurement of the cleaved PARP and caspase3 levels, two typical molecular markers for apoptosis. As shown in Figure 4d , the cleaved PARP and caspase3 are induced by doxorubicin (0.25-0.5 mM) in Ctrl-si-transfected MCF10A. In contrast, in Wsi#1-transfected MCF10A cells, the cleaved PARP and caspase3 are either undetectable or at low levels after treatment of doxorubicin (0.25-0.5 mM). Consistently, we noticed that the DNp63a protein levels are elevated in Wsi#1-transfected MCF10A cells without or with low concentration of doxorubicin. However, doxorubicin decreases the DNp63a protein levels in a dosage-dependent and WWP1-independent manner. The exact mechanism of DNp63a degradation by doxorubicin is currently unknown.
To further test whether WWP1 regulates apoptosis through targeting DNp63a for degradation, we knocked down both WWP1 and DNp63a in MCF10A and treated the cells with 0.25 mM doxorubicin (Figure 4e) . Consistent with the previous results, the WWP1 siRNA-transfected MCF10A cells show a higher level of DNp63a and lower levels of cleaved PARP and cleaved caspase 3 than the Ctrl-si-transfected MCF10A cells. As reported, 24 knockdown of DNp63a alone increases the levels of cleaved PARP and cleaved caspase 3. More importantly, knockdown of DNp63a abolishes the WWP1 siRNA-induced DNp63a increase and drug resistance. We also confirmed these results by the SRB assay (data not shown). These findings suggest that WWP1 regulates WWP1 targets the endogenous TAp63a protein for degradation and confers cell survival in a p53-independent manner. Based on the results in Figure  1-3, WWP1 targets not only DNp63a but also TAp63a for degradation. Numerous studies have shown that the endogenous TAp63a protein is usually at low levels in epithelial cells. 16 In a recent study, the endogenous TAp63a isoform is expressed in the HCT116 colon cancer cell line. 27 We validated the expression of TAp63a in Figure 1e . Therefore, we sought to test whether WWP1 targets endogenous TAp63a in HCT116 cells and regulates apoptosis. As shown in Figure 5a , we efficiently knocked down WWP1 in HCT116 using two different anti-WWP1 siRNAs. As expected, the endogenous TAp63a levels are elevated in WWP1 knockdown cells. WWP1 siRNA#2 causes a more significant increase of TAp63a than siRNA#1 possibly because of different knockdown efficiency in this cell line. Then we measured apoptosis by PARP cleavage. Consistent with the elevated TAp63a levels, the cleaved PARP protein level is increased in the WWP1 knockdown HCT116 cells. We confirmed this result by measuring cell viability with SRB assays. We found that both anti-WWP1 siRNAs significantly decrease HCT116 cell viability (Figure 5b) . Consistent with the higher levels of TAp63a and cleaved PARP, siRNA#2 more effectively decreases cell survival than siRNA#1. WWP1 has been shown to suppress p53 function. 13 To further determine whether WWP1 regulates apoptosis through p53 rather than TAp63a, we performed the same experiment in p53-null HCT116 cells. There is no significant difference between the p53-null HCT116 cells and the p53 WT HCT116 cells in terms of the induction of TAp63a, cleaved PARP and apoptosis by WWP1 siRNA. We noticed that WWP1 siRNA may decrease cell viability slightly more effective in p53 WT HCT116 cells than in p53-null cells. However, the p53 levels are not significantly changed by WWP1 knockdown (Figure 5a ). Furthermore, we measured apoptosis by Annexin V staining and found that WWP1 siRNA significantly increases Annexin V positive HCT116 cells (Figure 5c ). These findings indicate that WWP1 siRNAs induce TAp63a and apoptosis in a p53-independent manner. To study the biological relevance of WWP1-mediated degradation of TAp63a, we transfected WT TAp63a and the stable PY motif-mutated TAp63aY543F into HCT116 (p53À/À) cells and examined the proliferation/apoptosis index by SRB assays. We found that overexpression of TAp63a enhances cleaved caspase 3 and reduces cell viability when compared with the empty vector control (Supplementary Figure S2) . Consistent with the protein stability, the level of TAp63aY543F is higher than that of WT TAp63a. Compared with WT TAp63, TAp63aY543F induces more caspase 3 cleavages and cell viability loss.
As WWP1 siRNA induces apoptosis in both HCT116 WT and p53-null cells, we further tested whether inhibition of WWP1 sensitizes cells to chemotherapeutic drugs. The HCT116 cells were transfected with Ctrl-siRNA or WWP1 siRNA for 1 day and treated with different concentration of doxorubicin or cisplatin for 2 days. As shown in Figure 5c , WWP1 siRNA and both chemotherapeutic drugs additively decrease the cell viability. After combination with WWP1 siRNA, the half maximal inhibitory concentration (IC 50 ) for doxorubicin is decreased from 0.475 to 0.25 mM and the IC 50 for cisplatin is decreased from 75 to 32.5 mM. Similar results were obtained in HCT116 p53-null cells (data not shown).
DNA damage chemotherapeutic drugs induces WWP1 expression in a p53-dependent manner. We noticed that the WWP1 protein is induced by doxorubicin in a dosagedependent manner in MCF10A (Figure 4d ). We wondered whether WWP1 is also induced by doxorubicin in HCT116 cells. To test this, the WT and p53-null HCT116 cells were treated with 1 mM doxorubicin at different times. As a result, doxorubicin induces both p53 and WWP1 in WT HCT116 cells in a time-dependent manner (Figure 6a ). The induction peak for WWP1 is 48 h. Surprisingly, doxorubicin does not induce WWP1 in p53-null HCT116 cells. These results were conformed at mRNA levels by qRT-PCR (Figure 6b ). These results indicate that doxorubicin may induce WWP1 transcription in a p53-dependent manner.
To further test whether other DNA damage chemotherapeutic drugs also induce WWP1 in a p53-dependent manner, we treated the WT and p53-null HCT116 cells with different dosage of doxorubicin, cisplatin and etoposide. As shown in Figure 6c and d, both doxorubicin and cisplatin induce WWP1 in WT but not p53-null HCT116 cells in a dose-dependent manner. Similar results were observed with etoposide treatment (data not shown). These findings suggest that DNA damage chemotherapeutic drugs can induce the WWP1 expression in a p53-dependent manner. To further confirm these results in other cell lines other than HCT116, we treated MCF10A (WT p53) 28 and MDA-MB-468 (mutant p53) 29 with different concentration of doxorubicin for 48 h and found that WWP1 is only induced in MCF10A but not in MDA-MB-468 although p53 is accumulated in both cell lines (Figure 6e ).
The protein expression of WWP1 and p63 is reversely correlated in prostate and breast cancer cell lines. The p63 protein has been documented to be specifically expressed in normal basal epithelial cells but lost in cancer cells from the prostate and breast. 30, 31 In sharp contrast, WWP1 is frequently overexpressed in prostate and breast cancer cells. As WWP1 targets p63 for degradation, we asked whether the protein expression of WWP1 is negatively correlated with the protein expression of p63 in prostate and breast cancers.
We examined the protein expression levels of WWP1 and p63 in a panel of prostate and breast cell lines by western blot (Figure 7a-b) . Consistent with our previous report, 2 the protein levels of WWP1 are elevated in four prostate cancer cell lines LAPC-4, DU145, PC-3 and LNCaP/C4-2 compared with two immortalized prostate cell lines PZ-HPV7 and RWPE1 (Figure 7a ). The protein expression of p63 (mainly DNp63a isoform) is negatively correlated with the expression of WWP1 in all these cell lines. The only exception is 22Rv1, in which the expression of WWP1 is not increased but p63 is still undetectable. Similar results are obtained in 10 breast cancer cell lines and four immortalized breast cell lines (Figure 7b ). The only exception is HCC1937, in which the expression of WWP1 is increased but the DNp63 is still highly expressed. Therefore, we conclude that there is a negative correlation between WWP1 and p63 in a majority of prostate and breast cancer cell lines.
Discussion
In this study, we provide several lines of evidence to support that WWP1 targets the p63 protein for ubiquitin-mediated proteasomal degradation. First, WWP1 binds to p63a proteins through the WW/PY motif interaction. Second, WWP1 ubiquitinates p63a through its E3 ligase activity. Third, WWP1 promotes p63a for proteasomal degradation. In addition, the WWP1 siRNA upregulates the endogenous DNp63a and TAp63a protein levels. Finally, there is a negative correlation between the WWP1 and p63 proteins in prostate and breast cells.
It is well documented that p63 proteins have important functions in epithelial development and tumorigenesis through regulating epithelial progenitor cell proliferation, differentiation and apoptosis. 17, 18 p63 proteins are expressed in the basal cells of normal prostate glands but not in prostatic carcinomas. 30 Similarly, the expression of p63 proteins is in the nuclei of myoepithelial cells of normal breast ducts and lobules but not in invasive breast cancer except metaplastic carcinomas. 32 Several mechanisms including transcription regulation 20 and post-translational modification contribute to the loss of p63 protein expression in prostate and breast cancers. Increasing evidence suggests that protein ubiquitination and degradation have an important function for the p63 activity. [23] [24] [25] 33 Two other WWP1 family members, Itch and Nedd4, have been previously reported to target p63 proteins for proteasomal degradation. 24, 25 However, the expression levels of Itch in breast cancer are not altered 34 although the expression of Nedd4 has been found to be overexpressed in invasive bladder cancer cells. 4 WWP1 is amplified and overexpressed in more than 30% of prostate and breast cancers, suggesting that WWP1 among these E3 ligases may have a major function for the p63 protein degradation in prostate and breast cancers, although we cannot completely exclude the roles of Itch and Nedd4. Under the physiological conditions, how WWP1, Itch and Nedd4 are coordinately activated and specially recruit p63 need further investigation.
Importantly, different p63 isoforms have different biological functions. There are at least six isoforms of p63, a, b and g (each including TAp63 and DNp63). Numerous studies suggest that TAp63 isoforms induce apoptosis but DNp63 isoforms inhibit apoptosis. However, the functions of DNp63 from different reports are not consistent and sometimes even contradictory. DNp63 is essential for cancer cell survival through inhibiting TAp73 in squamous cell carcinoma (SCC) 35 and a subset of breast cancer with p53 mutation. 20 DNp63 has been reported to be overexpressed in primary SCCs of the Figure 7 Expression of the WWP1 and p63 proteins in prostate and breast cell lines. Western blots were performed in a panel of prostate (a) and breast (b) cell lines to determine the protein expression levels of WWP1 and p63. The controls are immortalized cell lines. The molecular weight markers are labeled at the right. Tubulin was used as a loading control. The protein expression level of WWP1 is negatively correlated with the protein expression level of p63a, especially DNp63a (*) in these samples head and neck. 36 Thus, it would be interesting to examine whether WWP1 is frequently downregulated in SCCs. However, DNp63a is proposed to act as a metastasis suppressor by maintaining the epithelial phenotype of cancer cells. 37 Loss of DNp63 has been reported to decrease epithelial cell adhesion and promote cell migration. 19 Furthermore, DNp63 has even been demonstrated to possess a growth suppression function. 38 p63 is frequently lost in most invasive adenocarcinomas including prostate cancer, 30 breast cancer, 31 bladder cancer 39 and lung cancer. 40 Therefore, the function of p63 may be context-dependent in different cancers. It is well established that the functions of p63 depend on the expression pattern of p53 family members. In breast carcinomas, DNp63 isoforms are co-expressed with TAp73 exclusively within a subset of triple-negative (ER/EGFR/ HER2 negative) primary breast cancers that commonly exhibit mutational inactivation of p53. 20 We demonstrated that WWP1 regulates both DNp63a and TAp63a isoforms in this study. WWP1 may target the b isoforms but not the g isoforms because both a and b, but not g, have a PY motif. However, WWP1 has been reported to suppress the function of p53 through nuclear export although p53 does not have a PY motif. 13 We found that WWP1 does not affect p53 stability in HCT116 and that WWP1 promotes p63 degradation independent of the p53 status (Figure 5a ). In addition, Itch has been reported to target p73 for ubiquitin-mediated degradation because p73 contains PY motifs. 41 Similarly, we found that WWP1 can also ubiquitinate p73 and decrease the stable level of p73 (unpublished observation). Thus, the functional output of WWP1 may rely on the expression pattern of p53 family members.
The expression pattern of p63 isoforms and p53 family members are different and complicated in different cancer cells. We found that WWP1 targets both DNp63a and TAp63a for degradation, implicating that WWP1 has a contextdependent role in terms of apoptosis and tumor development. Indeed, WWP1 sensitizes the MCF10A immortalized breast epithelial cells to doxorubicin-induced apoptosis but increases the HCT116 colon cancer cell survival and drug resistance. WWP1 is frequently amplified and overexpressed in prostate and breast cancers, suggesting that WWP1 overexpression may increase cell survival. In agreement with this idea, WWP1 knockdown in MCF7 and HCC1500 breast cancer cell lines causes apoptosis. 3 We do not know whether the WWP1 ablation-induced apoptosis in these cells is actually through the increase of TAp63 because we did not detect the increase of TAp63 by western blot (data not shown). However, we cannot exclude that TAp63 has a function because TAp63 isoforms can be transcriptionally active at the levels below the limit of detection by western blot. 42 Similarly, we cannot exclude that WWP1 promotes HCT116 cell survival through other molecules other than TAp63. The role and mechanistic action of WWP1 in cancer still need to be elucidated in vivo using transgenic mouse models.
WWP1 is amplified and overexpressed in over 40% of breast cancers and confers an advantage for cancer cell survival. In contrast, DNp63 is frequently lost in breast cancer cells. Apparently, the survival of the breast cancer cells with WWP1 overexpression does not depend on DNp63a. Only a small percentage of triple-negative breast cancers depend on DNp63 because TAp73 is overexpressed and p53 is mutated. 20 If WWP1 inhibits TAp73 in these cells, the cell survival would not require DNp63 any longer. Therefore, we would predict that WWP1 expression is very low in triplenegative breast cancer cells. Indeed, WWP1 is preferably overexpressed in ER positive and p53 WT breast cancers (www.Oncomine.org). The immunohistochemical staining results in invasive breast tumors confirmed that the expression of WWP1 associates with positive ER status (Chen et al., manuscript submitted). Therefore, the expression of WWP1 may be invaluable for breast cancer diagnosis and prognosis.
The transcriptional regulation of WWP1 is largely unknown although we have previously shown that WWP1 is induced by TGFb as a negative feedback mechanism. 1 Laine et al., 13 reported that UV-irradiation or g-irradiation decreases WWP1 mRNA expression in mouse embryonic fibroblasts in a p53-dependent manner. However, we found that several DNA damage chemotherapeutic drugs including doxorubicin, cisplatin and etoposide induces the WWP1 expression in HCT116 and breast cell lines in a p53-dependent manner. These conflicting results may be caused by different treatments in different cells. Whether WWP1 is an Mdm2 like p53 direct target gene needs elucidation in future studies.
In summary, we demonstrate that WWP1 targets p63 proteins for ubiquitin-mediated proteasomal degradation. We show that WWP1 plays opposite roles in terms of apoptosis and drug sensitivity in immortalized cells and cancer cells depending on the expression of different p63 isoforms. Given the frequent gene amplification and overexpression of WWP1 in prostate and breast cancers, these findings may help us understand the role of WWP1 in cancer development and may provide rationale to develop WWP1 as a diagnosis marker and molecular target for cancer therapy.
Materials and Methods
Cell culture and transfection. All breast and prostate cell lines have been described in our previous studies. 3, 43, 44 The human embryonic kidney 293T-derived LinX cell line was cultured in DMEM containing 5% fetal bovine serum (FBS) and 1% penicillin and streptomycin (PS). The p53 wild type (WT) and p53-null HCT116 colon cancer cell lines were grown in HyQ s McCOY'S 5A medium with 5% FBS and 1% PS. All transient transfection for plasmids and siRNAs was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction. All chemically synthesized siRNAs were purchased from Dharmacon (Chicago, IL, USA) and transfected at 100 nM final concentration. The siRNA target sequences for human WWP1 gene are 5 0 -GAAGTCA TCTGTAACTAAA-3 0 (Wsi#1) and 5 0 -GCAGAGAAATACTGTTTAT-3 0 (Wsi#2). The target sequence for DNp63a is 5 0 -CAGGTTGGCACTGAATTCACG-3 0 . The 3 0 -UU overhang for both strands and 5 0 -phophorylation for anti-sense sequence were employed for these siRNAs.
Expression plasmids. The plasmids expressing WT WWP1, the catalytic inactive hWWP1C890A, and mWWP1C886S have been described in our previous studies. 3, 12 The Myc-Ub construct pCMV-6XHis-Myc-Ub is a gift from Dr. Raymond J. Deshaies (California Institute of Technology). The pcDNA3-FLAG-TAp63a and pcDNA3-FLAG-DNp63a constructs were obtained by subcloning the TAp63a and DNp63a cDNA into the Hind III and Not I sites of pcDNA3. The PY motif-mutated FLAG-TAp63aY543F and FLAG-DNp63aY449F were obtained by using a QuikChange s site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). Constructs for GST-WW domains were obtained by subcloning the DNA fragments encoding the WW domains of hWWP1 into the BamH I and Not I sites of the pEBG vector.
Immunoprecipitation and GST pull down. Immunoprecipitation using an anti-Myc antibody (Ab) plus protein A-agarose beads and GST pull down using the glutathione-Sepharose 4B slurry beads have been described in a previous study. 12 Briefly, LinX cells were transfected with expression plasmids in 60-mm culture dishes for 48 h. The cells from each dish were collected into 0.6 ml of 1 Â ice-cold cell lysis buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% protease inhibitor cocktail (no. P8340, Sigma, St. Louis, MO, USA) ) and incubated on ice for 30 min. Then, cell lysates were centrifuged at 10 000 g for 10 min at 41C. The supernatant (200 ml) and primary anti-Myc antibody (2 ml) were incubated with gentle rocking overnight at 41C. In all 30 ml of 50% protein A-agarose beads were added and incubated for 1-3 h at 41C. The anti-WWP1 mouse monoclonal Ab (1A7) was used to replace anti-Myc Ab to immunoprecipitate the endogenous WWP1 proteins from MCF10A. The mouse IgG was used as the negative control. For the GST pull-down assay, the glutathione-Sepharose 4B slurry beads were directly incubated with the supernatant overnight at 41C. The beads were washed five times with 500 ml of 1 Â cell lysis buffer. Proteins were resuspended with 20-50 ml of SDS sample buffer and analyzed by western blot.
Antibodies and western blot. The anti-WWP1 rabbit polyclonal antibody (Ab) has been described in our previous report (3) . The anti-WWP1 mouse monoclonal Ab (1A7) is from Novus Biologicals Inc. (Littleton, CO, USA). The anti-b-actin mouse monoclonal Ab AC-15 (no. A5441), the anti-FLAG rabbit polyclonal Ab (no. F7425), the anti-GST rabbit polyclonal Ab (no. G7781) are from Sigma. The antip63 mouse monoclonal Ab 4A4 (no. Sc-8431), anti-Myc mouse monoclonal Ab 9B11 (no. 2276), anti-PARP (no. 9915), anti-caspase 3 (no. 9915), and anti-tubulin antibodies (no. 2148) are from Cell Signaling (Danvers, MA, USA). The anti-p53 mouse monoclonal Ab (no. 554169) is from BD Pharmingen (San Diego, CA, USA).
Proteins were separated by SDS-PAGE and blotted onto PVDF membranes. The membranes were blocked with PBST (PBS with 0.1% Tween 20) buffer containing 5% nonfat dry milk and incubated with primary antibodies diluted in PBST overnight at 41C. After washing three times in PBST, the membranes were incubated with 10 000 times diluted horseradish peroxidase-conjugated second antibodies for 1 h at room temperature. Detection was performed with the Supersignal West Pico enhanced chemiluminescence system (Pierce, Rockford, IL, USA) and a LAS-3000 Fujifilm imaging system. Protein ubiquitination assay. LinX cells were transiently transfected with Myc-Ub and other plasmids as necessary in 6-well plates. Two days after transfection, the cells were harvested in 150 ml SDS lysis buffer (50 mM Tris-Cl, pH 6.8, 1.5% SDS). The samples were boiled for 15 min. 100 ml of protein lysate was diluted with 1.2 ml EBC/BSA buffer (50 mM Tris-Cl, pH 6.8, 180 mM NaCl, 0.5% CA630, 0.5% BSA) and incubated with 30 ml 50% anti-FLAG s M2-agarose beads (no. A2220, Sigma) overnight at 41C with rotation. The beads were collected by centrifugation at 10 000 g for 30 s at 41C and washed three times with 1 ml ice-cold EBC/BSA buffer. Proteins were resuspended with 30 ml of SDS sample buffer and analyzed by western blot. Ub-conjugated p63 was detected by anti-Myc Ab. For the endogenous p63 ubiquitination, IP was performed by using anti-p63 Ab; and ubiquitinated p63 was detected by anti-Ub Ab.
Measurement of apoptosis. The siRNA-transfected MCF10A and HCT116 cells were exposed to different concentrations of doxorubicin (Sigma) or Cisplatin (Cpt) at different times. The cell viability was measured by the SRB assay and the Annexin V staining as described in our previous report. 2 The protein levels of cleaved PARP and/or cleaved caspase 3 were used to measure apoptosis.
